Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Urologic Neoplasms 1Urogenital Neoplasms 1Penile Neoplasms 1Non-Small Cell Lung Cancer With HER2- Mutations 1Melanoma 1Male Urogenital Diseases 1Lung Neoplasms 1First-line Advanced NSCLC Patients 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1

Interventions

Cisplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Non-Small Cell Lung Cancer With HER2- Mutations × CP protocol × Clear all
NCT06430437 2026-01-21

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
300 enrolled
Thoracic

Non-Small Cell Lung Cancer With HER2- Mutations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡